Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Bio-Rad Laboratories, Inc. reported revenue of $2.58B, up 0.7% year over year. Operating margin was 1.8% and net margin 29.4%, on a free-cash-flow margin of 14.5% with capital expenditure at 6.1% of revenue. Every figure is computed directly from BIO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $2.58B | 1.8% | 29.4% |
| FY2024 | $2.57B | 10.5% | -71.9% |
| FY2023 | $2.67B | 12.6% | -23.9% |
| FY2022 | $2.80B | 17.2% | -129.5% |
| FY2021 | $2.92B | 17.1% | 145.6% |
How does BIO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: TMO · NOC · MDT · SYK · MMM · DHR
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.